“Buying from a reputable manufacturer is crucial, because it matters how the plant is cultivated and processed,” Dr. Maroon says. One clue that a company is cutting corners: too low a cost. Good CBD is pricey—a bottle of high-quality capsules is sold in Cohen’s office for $140. But for many, it’s worth the money. Roth spent $60 on her tiny bottle. But when her energy returned the day she started taking CBD, she decided that was a small price to pay.
Brian Peterson has been a CBD consumer advocate and educator since 2013. He is the founder and managing editor of the CBDOilUsers.com website. He's also the lead administrator of the CBD Oil Users Group, the largest CBD group on Facebook. His passion is educating consumers so that they can make their own decisions when purchasing and using CBD products.
CBD has proven neuroprotective effects and its anti-cancer properties are being investigated at several academic research centers in the United States and elsewhere. A 2010 brain cancer study by California scientists found that CBD “enhances the inhibitory effects of THC on human glioblastoma cell proliferation and survival.” This means that CBD makes THC even more potent as an anticancer substance. Also in 2010, German researchers reported that CBD stimulates neurogenesis, the growth of new brain cells, in adult mammals.
In order to determine which companies were included on this best cbd oil list and how they were ranked, each prominent provider on the market (Note: we pulled our list of brands from other established and credible CBD rankings like: this one and this one.) was allocated six individual Rank Scores based on their performance in the following metrics:
To make matters more confusing, nine states (including California, Washington, and Colorado) let residents buy cannabis-based products with or without THC. Nearly two dozen other “medical marijuana states” allow the sale of cannabis, including capsules, tinctures, and other items containing CBD or THC, at licensed dispensaries to people whose doctors have certified that they have an approved condition (the list varies by state but includes chronic pain, PTSD, cancer, autism, Crohn’s disease, and multiple sclerosis). Sixteen more states legalized CBD for certain diseases.
Cutting-edge science has shown that the endocannabinoid system is dysregulated in nearly all pathological conditions. Thus, it stands to reason that “modulating endocannabinoid system activity may have therapeutic potential in almost all diseases affecting humans,” as Pal Pacher and George Kunos, scientists with the U.S. National Institutes of Health (NIH), suggested in a 2014 publication.